Demographic and clinical characteristics of patients with hereditary angioedema in Canada

Ann Allergy Asthma Immunol. 2022 Jan;128(1):89-94.e1. doi: 10.1016/j.anai.2021.07.015. Epub 2021 Jul 20.

Abstract

Background: Data on the clinical and demographic features of Canadian patients with hereditary angioedema (HAE) are lacking.

Objective: To describe the clinical and demographic features in a large Canadian HAE cohort and compare them with patients with HAE in other countries.

Methods: An online questionnaire was distributed to the members of 2 Canadian HAE patient groups to collect information on demographics and HAE clinical characteristics. All participants 18 years of age or older with HAE type I or II were eligible. Frequency, location, prodromes, and triggers of HAE attacks, including types of HAE treatment, were characterized.

Results: Among the 90 participants who completed the online survey, 57% self-identified as having HAE type 1 and 26% HAE type II. The average diagnostic delay was 11 years. In the preceding 6 months, 24% of the participants had no attacks and 35% experienced greater than 5 attacks. The most frequently affected regions of the body were the abdomen (83%), arms orlegs (63%), face (41%), and larynx or throat (41%). Approximately 87% of the participants reported having access to C1 inhibitor at home, and 69% reported using it for long-term prophylaxis.

Conclusion: Canadian patients with HAE share common clinical characteristics with patients with HAE in other countries. They had a delay in HAE diagnosis and a high burden of disease, as indicated by the high frequency of attacks in the preceding 6 months. This study provides a better understanding of the demographic and clinical characteristics of Canadian patients with HAE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angioedemas, Hereditary* / diagnosis
  • Angioedemas, Hereditary* / drug therapy
  • Angioedemas, Hereditary* / epidemiology
  • Canada / epidemiology
  • Complement C1 Inhibitor Protein
  • Delayed Diagnosis
  • Humans
  • Surveys and Questionnaires

Substances

  • Complement C1 Inhibitor Protein